In recent years, the pharmaceutical industry has witnessed frequent policy adjustments, intensifying market competition and continuous growth in R&D investment. Innovative pharmaceutical enterprises are generally under great financial pressure. As a typical innovative drug R&D enterprise, Dizhe Pharmaceuticals inevitably faces difficulties such as capital shortage, high R&D investment, and slow commercialization. Adopting the combined method of case analysis and financial indicator analysis, this paper systematically sorts out the financial breakthrough paths of Dizhe Pharmaceuticals. The research concludes that Dizhe Pharmaceuticals relieves financial pressure and resists financial risks through pipeline focus, accelerated commercialization, capital structure optimization, and external strategic collaboration, and effectively improves its long-term value creation capability. This case provides a reference for similar innovative pharmaceutical enterprises.